Core Viewpoint - The stock of Basilea Pharmaceutica (02616) surged over 8% towards the end of trading, with a current increase of 6.73%, reaching HKD 6.66, and a trading volume of HKD 93.123 million, following the approval of a new indication for Sugli monoclonal antibody by the UK MHRA for treating specific adult patients with non-small cell lung cancer (NSCLC) [1] Company Developments - Basilea Pharmaceutica announced that the UK MHRA has approved the new indication for Sugli monoclonal antibody, which is to be used as a monotherapy for adult patients with unresectable stage III NSCLC who have PD-L1 expression ≥1%, no EGFR sensitive mutations, or ALK/ROS1 genomic alterations, and have not shown disease progression after platinum-based chemoradiotherapy [1] - According to a report from Ping An Securities, Basilea Pharmaceutica is leveraging clinical development as a driving force, with its R&D 1.0 phase commercial products contributing reliable cash flow, while the R&D 2.0 phase focuses on innovative project layouts and cutting-edge technologies [1] Financial Projections - The core products of Basilea Pharmaceutica have entered clinical trial stages, and the company is expected to continue advancing candidate projects into clinical trials [1] - Revenue projections for Basilea Pharmaceutica are estimated to reach HKD 195 million, HKD 464 million, and HKD 633 million for the years 2025, 2026, and 2027, respectively, with the initial coverage rating set at "Recommended" [1]
港股异动 | 基石药业-B(02616)尾盘涨超8% 舒格利单抗III期非小细胞肺癌新适应症获英国MHRA批准